Document:

Filed by sedaredgar.com - Anavex Life Sciences Corp. - Exhibit 10.1

CONSULTANT SERVICES AGREEMENT

This Agreement is made this 1st day of July, 2009,
between:

1. NAD Ltd, a company duly constituted and lawfully
operating under the laws of Cyprus, having its registered seat at 30 Tempon
Street, Engomi, PO Box 28006, Nicosia, legally represented by Dr. Nick Demos,
legally authorized for the signature of the present agreement (hereinafter the
“Consultant”), and

2. ANAVEX Life Sciences Corp., a company duly
constituted and lawfully operating under the laws of the state of Nevada, USA,
having its representative office, in Geneva, Switzerland, (hereinafter the
“Company”).

Each of the Company and the Consultant shall hereinafter be
referred to as the “Party” and, together with each other, the “Parties”.

The provisions of the Preamble contain substantive provisions,
giving rise to rights, claims and obligations in favour of, or against, the
Parties.

Preamble

Whereas the Consultant represents and warrants to the Company
that it is an experienced operator at providing investor relations consultancy
and related programme implementation services;

Whereas the Consultant is interested in providing the Company,
with the below mentioned services, and the Company, acting on its own behalf is
accepting the same, subject to the following terms and conditions;

1. Services

The Consultant shall provide to the Company, with domestic and
international investor relations consultancy and associated programme
implementation services, and shall also act as a Company financial
communications partner. More specifically, the Consultant shall develop and
implement, locally and abroad, investor and public relations strategies and
shall manage their ongoing investor relations, with a view, inter alia, to
helping the Company:

	* 	
      Strengthen their relationship with investors,
      shareholders, fund managers, analysts, etc. (hereinafter the “Interested
      Persons”); and

	 	 
	* 	
      Articulating and presenting its business strategy and
      financial performance to Interested Persons.

2. Commencement and Duration of the Agreement

2.1 The term of this Agreement shall be one (1) calendar year,
commencing on 1st day of July, 2009 and expiring, unless earlier
terminated, on 30th day of April, 2010, and an option to extent for
one more year.

2.2 Either party may terminate this Agreement by giving the
other party 30 days written notice of termination.

2.3 Upon termination the Consultant shall have 30 days to
exercise any options that have already vested. After 30 days any unexercised
options shall become void and of no further effect All non-vested options at the
time of termination or death shall become immediately void and of no further
effect.

3. Fees

The Consultant will charge an annual retainer fee of $4000.00
USD per month, invoiced monthly, at the beginning of each month. The fees will
be paid in any bank account following prior written notification by the
Company.

4. Placement and other Bonus Success

If, during the period that is the Consultant is retained by the
Company under this Agreement or within 12 months after termination or expiration
of this engagement (subject that a letter of intent, definitive agreement or
other similar such document is agreed to prior to termination of our
engagement), any business relationship is contracted with any strategic partner
introduced by NAD Ltd to, the following fees shall become payable: 

	In case of an equity investment by a financial partner into the ANAVEX
  group of companies, a success fee of 2.0% of the equity funds contributed
  becomes payable within 10 business days after the equity funds have been
  raised by the Consultant.
  
	In case of an equity investment by a strategic partner into the ANAVEX
  group of companies, a success fee of 2.0% of the equity funds contributed
  becomes payable within 10 business days after the equity funds have been
  raised by the Consultant.
  
	In case of an loan investment into, a bond issue by or a guarantee given
  to ANAVEX group, a success fee of 1.0% of the loan, bond or guarantee volume
  becomes payable within 10 business days after the respective funds have been
  raised by the Consultant. 

5. Stock Options

The Consultant will be issued 120,000 Share purchase options
subject to the terms and conditions as outlined in Schedule 1 as attached.

6. Expenses

The Company will reimburse to the Consultant all reasonable
expenses incurred directly related to the Consultants efforts to carry out his
obligations for this Agreement. Amounts exceeding $1000 per month will require
written authorization from the Company prior to incurring of the charges.

7. Waiver of Rights

No failure by either Party to exercise, nor any delay by either
Party in exercising any right or remedy hereunder shall operate as a waiver
thereof, nor any single or partial exercise of any right or remedy prevent any
further or other exercise thereof or the exercise of any other right or remedy.
The rights and remedies herein provided are cumulative and not exclusive of any
rights or remedies provided by law.

8. Modifications

Any modification of the present agreement all of the terms of
which are regarded as essential will be effectuated by mutual agreement, in
writing and signed by each party whose rights hereunder are effected
thereby.

9. Notifications

The correspondence and any other communication between the
parties will be conducted in the English language. The letters will be delivered
to the contracting parties to the above mentioned addresses respectively.

10. Settlement of Disputes

This Agreement shall be governed, construed and enforced in
accordance with the laws of Greece. The Parties submit to the exclusive
jurisdiction of the competent courts of Athens in regard to any disputes that
may arise from or in connection with this Agreement and cannot be settled
amicably within a reasonable period of time.

2

11. Miscellaneous

11.1 Neither Party shall disclose or cause to be
disclosed: [(i) the existence, execution and contents of this Agreement], and
(ii) any information, data or documents which either Party may have obtained, by
virtue of, in connection with, or in the course of, this Agreement and the
discharge of the functions envisaged therein, in relation to the other Party,
its Group members, shareholders, employees, officers and advisors, without the
prior written consent of the other Party, unless directed by a court or other
authority or for the purpose of safeguarding its legitimate rights and interests
hereunder. The confidentiality obligation shall survive termination of this
Agreement and breach thereof shall qualify as due cause for termination of this
Agreement against the breaching party.

11.2 Each Party shall execute or cause to be executed
such additional documents and take such other actions necessary or advisable to
give full effect to the terms of this Agreement.

11.3 This Agreement supersedes any and all prior
agreements, understandings, communications or contracts entered into or
exchanged between the Parties on the subject matter.

IN WITNESS WHEREOF, the Parties have executed this
Agreement on the date first above written, in July 1, 2009 counterparts, each of
which shall, for all purposes, be deemed as original, but all of which together
shall constitute one and the same legal instrument.

The Contracting Parties

For the Company: ANAVEX Life Sciences Group Harvey
Lalach

For the Consultant: NAD Ltd Nick Demos

Date: July 1, 2009

3

SCHEDULE 1

STOCK OPTION AGREEMENT

This Stock Option Agreement is made as of July 1, 2009 by and
between Anavex Life Sciences Corp. (the “Corporation”), and NAD Ltd. (the
“Optionee”).

RECITALS

A. The Corporation and the Optionee have entered into a
Consulting Agreement dated as of July 1, 2009 (the “Consulting Agreement”) that
provides for the grant of stock options to the Optionee to purchase shares of
the Corporation’s common stock (the “Shares”). The stock options granted herein
are being granted pursuant to the Consulting Agreement. 

NOW THEREFORE, specifically incorporating these recitals
herein, it is agreed as follows:

AGREEMENT

GRANT OF OPTIONS

NUMBER OF SHARES. Subject to the terms and conditions of this
Agreement and the Consulting Agreement, the Corporation grants to Optionee,
Options to purchase from the Corporation One hundred thousand (120,000) shares
(the “Option Shares”).

EXERCISE PRICE. Each Option Share is
exercisable at a price of US $2.50 per share (the “Option Price”).

TERM. The Expiration Date for all
Options shall be July 1, 2014.

VESTING. The Options granted herein
vest in accordance with the terms set out below:

All options to vest upon completion of a minimum financing of
$3,000,000 introduced and closed by the Optionee.

CONDITIONS OF OPTION.

The Options may be exercised immediately upon vesting, subject
to the terms and conditions as set forth in this Agreement and the Consulting
Agreement.

EXERCISE OF OPTION

DATE EXERCISABLE. The Options shall become exercisable by
Optionee in accordance with the vesting terms as above.

MANNER OF EXERCISE OF OPTIONS AND PAYMENT FOR COMMON STOCK. The
Options may be exercised by the Optionee, in whole or in part, by giving written
notice to the Secretary of the Corporation, setting forth the number of Shares
with respect to which Options are being exercised. The purchase price of the
Option Shares upon exercise of the Options by the Optionee shall be paid in full
in cash.

4

STOCK CERTIFICATES.

Promptly after any exercise in whole or in part of the Options
by Optionee, the Corporation shall deliver to Optionee a certificate or
certificates for the number of Shares with respect to which the Options were so
exercised, registered in Optionee name.

NONTRANSFERABILITY RESTRICTION.

The Options are not transferable by Optionee.

NO RIGHTS AS SHAREHOLDER PRIOR TO EXERCISE

Optionee shall not be deemed for any purpose to be a
shareholder of Corporation with respect to any shares subject to the Options
under this Agreement to which the Options shall not have been exercised.

ADJUSTMENTS

NO EFFECT ON CHANGES IN CORPORATION’S CAPITAL STRUCTURE. The
existence of the Options shall not affect in any way the right or power of the
Corporation or its shareholders to make or authorize any adjustments,
recapitalization, reorganization, or other changes in the Corporation’s capital
structure or its business, or any merger or consolidation of the Corporation, or
any issue of bonds, debentures, preferred or preference stocks ahead of or
affecting the Option Shares, or the dissolution or liquidation of the
Corporation, or any sale or transfer of all or any part of its assets or
business, or any other corporate act or proceeding, whether of a similar
character or otherwise.

ADJUSTMENT TO OPTION SHARES.

The Option Shares are subject to adjustment upon
recapitalization, reclassification, consolidation, merger, reorganization, stock
dividend, reverse or forward stock split and the like. If the Corporation shall
be reorganized, consolidated or merged with another corporation, Optionee shall
be entitled to receive upon the exercise of the Option the same number and kind
of shares of stock or the same amount of property, cash or securities as
Optionee would have been entitled to receive upon the happening of any such
corporate event as if Optionee had been, immediately prior to such event, the
holder of the number of Shares covered by the Option.

5

IN WITNESS WHEREOF, the parties hereto have executed this
Agreement as of the date first above written.

	Anavex Life Sciences Corp. 	 
	 	 
	/s/ Harvey Lalach	 
	Name: Harvey Lalach 	 
	Title: President 	 

The undersigned Optionee hereby acknowledges receipt of this
Stock Option Agreement, accepts the Options granted there under, and agrees to
the terms and conditions thereof and the related Consultant Agreement.

	OPTIONEE 	 
	 	 
	/s/ Nick Demos	 
	NAD Ltd. 	 

6

Anavex Life Sciences Corp.

NOTICE OF EXERCISE OF STOCK OPTION

The undersigned hereby exercises the Stock Options granted by
Anavex Life Sciences Corp. and seeks to purchase
____________________ shares
of Common Stock of the Corporation pursuant to said Options. The undersigned
understands that this exercise is subject to all the terms and provisions of the
Stock Option Agreement dated as of May 1, 2009 and of the Consulting Agreement
referred to therein.

Enclosed is a check in the sum of US $________________in
payment for such shares.

	 	 
	Signature of Optionee 	 
	 	 	 
	 	 	 
	Date: 	 	 

7Filed by sedaredgar.com - Anavex Life Science - Exhibit 10.2

NONE OF THE SECURITIES TO WHICH THIS PRIVATE PLACEMENT
SUBSCRIPTION RELATES HAVE BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT
OF 1933, AS AMENDED (THE "1933 ACT"), OR ANY U.S. STATE SECURITIES LAWS, AND,
UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE
UNITED STATES (AS DEFINED HEREIN) OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH
THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE
CONDUCTED UNLESS IN COMPLIANCE WITH THE 1933 ACT. "UNITED STATES" AND "U.S.
PERSON" ARE AS DEFINED BY REGULATION S UNDER THE 1933 ACT.

PRIVATE PLACEMENT SUBSCRIPTION 
FOR NON U.S., NON-CANADIAN
SUBSCRIBERS

ANAVEX LIFE SCIENCES CORP.

INSTRUCTIONS TO SUBSCRIBER:

	1. 	
      THIS OFFERING IS NOT AVAILABLE TO RESIDENTS OF THE
      UNITED STATES OR CANADA.

	 	 
	2. 	
      COMPLETE the information on page 11 of this
      Subscription.

	 	 
	3. 	
      WIRE the Subscription Proceeds to Anavex Life
      Sciences Corp pursuant to the wire instructions provided by the Company,
      or deliver a $US bank draft.

	 	 
	4. 	
      FAX a copy of page 11 of this Subscription, and
      all pages of the applicable Schedules of this Subscription to Harvey
      Lalach, President Anavex Life Sciences Corp., at 30 210 603
4026.

	 	 
	5. 	
      COURIER the originally executed copy of the entire
      Subscription, together with all duly signed Schedules, to Anavex Life
      Sciences Corp. to

Anavex Life Sciences Corp. 
27 Marathonos Ave.
15351
Athens, Greece

NOTE there are contractual resale restrictions set out in
this Subscription in addition to resale restrictions imposed by law.

If you have any questions please contact Harvey Lalach,
President of the Company, at: 30 210 603 4026 .

- 2 -

NONE OF THE SECURITIES TO WHICH THIS PRIVATE PLACEMENT
SUBSCRIPTION RELATES HAVE BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT
OF 1933, AS AMENDED (THE "1933 ACT"), OR ANY U.S. STATE SECURITIES LAWS, AND,
UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE
UNITED STATES (AS DEFINED HEREIN) OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH
THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE
CONDUCTED UNLESS IN COMPLIANCE WITH THE 1933 ACT. "UNITED STATES" AND "U.S.
PERSON" ARE AS DEFINED BY REGULATION S UNDER THE 1933 ACT.

PRIVATE PLACEMENT SUBSCRIPTION

(Non U.S. Subscribers Only)

	TO: 	ANAVEX LIFE SCIENCES CORP.
      (the "Company") 
	  	Athens, Greece

Purchase of Units

1. Subscription

1.1 The undersigned (the "Subscriber") hereby irrevocably
subscribes for and agrees to purchase the number of units (the “Units”) of the
Company as set out on page 11 of this Subscription at a price of US$2.25 per
Unit (such subscription and agreement to purchase being the "Subscription"), for
the total subscription price as set out on page 11 of this Subscription (the
"Subscription Proceeds"), which Subscription Proceeds are tendered herewith, on
the basis of the representations and warranties and subject to the terms and
conditions set forth herein. The total offering is intended to be $700,000 but
may be more or less in the discretion of the Company. The Shares are also
referred to as the “Securities”.

1.2 Each Unit will consist of one share of common stock in the
capital of the Company (each, a “Share”) and 1.125 (one and one eighth) share
purchase warrants (each, a “Warrant”) subject to adjustment. Each full Warrant
shall be non-transferable. Each full Warrant shall entitle the holder thereof to
purchase one share of common stock in the capital of the Company (each, a
“Warrant Share”), as presently constituted for a period of two years commencing
from the Closing (as defined hereafter), at a price per Warrant Share of
US$2.25. Certificates representing the Warrants will be in the form attached as
Exhibit A. The Shares, Warrants and Warrant Shares are referred to herein as the
“Securities”.

1.3 The Company hereby agrees to sell, on the basis of the
representations and warranties and subject to the terms and conditions set forth
herein, to the Subscriber the Securities. Subject to the terms hereof, the
Subscription will be effective upon its acceptance by the Company.

1.4 Unless otherwise provided, all dollar amounts referred to
in this Subscription are in lawful money of the United States of America.

- 3 -

2. Payment

2.1 The Subscription Proceeds must accompany this Subscription
and shall be wired directly to the Company's account in accordance with the wire
instructions as provided by the Company or delivering a $US banker’s check.
Where the Subscription Proceeds are paid to the Company, the Company may treat
the Subscription Proceeds as a non-interest bearing loan and may use the
Subscription Proceeds prior to this subscription being accepted by the
Company.

2.2 The Subscriber shall complete, sign and return to the
Company as soon as possible, on request by the Company, any documents,
questionnaires, notices and undertakings as may be required by regulatory
authorities, the OTC Bulletin Board, stock exchanges and applicable law.

2.3 The Subscriber acknowledges that the Company may pay
finders’ fees to finders in connection with this placement on terms negotiated
and approved by the Company. 

3. Closing

3.1 Closing of the purchase and sale of the Units shall occur
on or before October 24, 2009, or on such other date as may be determined by the
Company in its sole discretion (the "Closing Date"). The Subscriber acknowledges
that Units may be issued to other subscribers under this offering (the
"Offering") before or after the Closing Date (the last sale of Units under this
Offering being referred to as the "Final Closing Date").

4. Acknowledgements of Subscriber

4.1 The Subscriber acknowledges and agrees that:

	 	(a) 	
      the Securities have not been registered under the
      Securities Act of 1933, as amended (the "1933 Act"), or under any state
      securities or "blue sky" laws of any state of the United States, and are
      being offered only in a transaction not involving any public offering
      within the meaning of the 1933 Act, and, unless so registered, may not be
      offered or sold in the United States or to U.S. Persons (as defined
      herein), except pursuant to an effective registration statement under the
      1933 Act, or pursuant to an exemption from, or in a transaction not
      subject to, the registration requirements of the 1933 Act, and in each
      case only in accordance with applicable state securities laws;

	 	 	 
	 	(b) 	
      the Company will refuse to register any transfer of the
      Securities not made in accordance with the provisions of Regulation S,
      pursuant to an effective registration statement under the 1933 Act or
      pursuant to an available exemption from, or in a transaction not subject
      to, the registration requirements of the 1933 Act;

	 	 	 
	 	(c) 	
      the decision to execute this Subscription and purchase
      the Securities agreed to be purchased hereunder has not been based upon
      any oral or written representation as to fact or otherwise made by or on
      behalf of the Company and such decision is based solely upon a review of
      publicly available information regarding the Company available on the
      website of the United States Securities and Exchange Commission (the
      "SEC") available at www.sec.gov (the "Company Information");

	 	 	 
	 	(d) 	
      the Subscriber and the Subscriber's advisor(s) have had a
      reasonable opportunity to review the Company Information and to ask
      questions of and receive answers from the Company regarding the Offering,
      and to obtain additional information, to the extent possessed or
      obtainable without unreasonable effort or expense, necessary to verify the
      accuracy of the information contained in the Company Information, or any
      other document provided to the Subscriber;

- 4 -

	 	(e) 	
      the books and records of the Company were available upon
      reasonable notice for inspection, subject to certain confidentiality
      restrictions, by the Subscriber during reasonable business hours at its
      principal place of business and that all documents, records and books
      pertaining to this Offering have been made available for inspection by the
      Subscriber, the Subscriber's attorney and/or advisor(s);

	 	 	 
	 	(f) 	
      by execution hereof the Subscriber has waived the need
      for the Company to communicate its acceptance of the purchase of the Units
      pursuant to this Subscription;

	 	 	 
	 	(g) 	
      the Company is entitled to rely on the representations
      and warranties and the statements and answers of the Subscriber contained
      in this Subscription and the Subscriber will hold harmless the Company
      from any loss or damage it may suffer as a result of the Subscriber's
      failure to correctly complete this Subscription;

	 	 	 
	 	(h) 	
      the Subscriber will indemnify and hold harmless the
      Company and, where applicable, its respective directors, officers,
      employees, agents, advisors and shareholders from and against any and all
      loss, liability, claim, damage and expense whatsoever (including, but not
      limited to, any and all fees, costs and expenses whatsoever reasonably
      incurred in investigating, preparing or defending against any claim,
      lawsuit, administrative proceeding or investigation whether commenced or
      threatened) arising out of or based upon any acknowledgment,
      representation or warranty of the Subscriber contained herein or in any
      other document furnished by the Subscriber to the Company in connection
      herewith, being untrue in any material respect or any breach or failure by
      the Subscriber to comply with any covenant or agreement made by the
      Subscriber to the Company in connection therewith;

	 	 	 
	 	(i) 	
      the issuance and sale of the Securities to the Subscriber
      will not be completed if it would be unlawful or if, in the discretion of
      the Company acting reasonably, it is not in the best interests of the
      Company;

	 	 	 
	 	(j) 	
      the Subscriber has not acquired the Securities as a
      result of, and will not itself engage in, any "directed selling efforts"
      (as defined in Regulation S under the 1933 Act) in the United States in
      respect of any of the Units which would include any activities undertaken
      for the purpose of, or that could reasonably be expected to have the
      effect of, conditioning the market in the United States for the resale of
      any of the Units; provided, however, that the Subscriber may sell or
      otherwise dispose of any of the Securities pursuant to registration of any
      of the Shares pursuant to the 1933 Act and any applicable state securities
      laws or under an exemption from such registration requirements and as
      otherwise provided herein;

	 	 	 
	 	(k) 	
      the Subscriber is outside the United States when
      receiving and executing this Subscription and is acquiring the Securities
      as principal for its own account, for investment purposes only, and not
      with a view to, or for, resale, distribution or fractionalization thereof,
      in whole or in part, and no other person has a direct or indirect
      beneficial interest in such Securities;

	 	 	 
	 	(l) 	
      none of the Securities may be offered or sold to a U.S.
      Person or for the account or benefit of a U.S. Person (other than a
      distributor) prior to the end of the expiration of a period of one year
      after the date of original issuance of the Securities;

	 	 	 
	 	(m) 	
      the statutory and regulatory basis for the exemption
      claimed for the offer and sale of the Securities, although in technical
      compliance with Regulation S, would not be available if the offering is
      part of a plan or scheme to evade the registration provisions of the 1933
      Act;

	 	 	 
	 	(n) 	
      the Subscriber has been advised to consult its own legal,
      tax and other advisors with respect to the merits and risks of an
      investment in the Securities and with respect to applicable resale
      restrictions and it is solely responsible (and the Company is in any way
      responsible) for compliance with applicable resale
  restrictions;

- 5 -

	 	(o) 	
      the Securities are not listed on any stock exchange or
      automated dealer quotation system and no representation has been made to
      the Subscriber that any of the Securities will become listed on any stock
      exchange or automated dealer quotation system, except that currently
      certain market makers make market in the shares of the Company's common
      stock on the OTC Bulletin Board;

	 	 	 
	 	(p) 	
      neither the SEC nor any other securities commission or
      similar regulatory authority has reviewed or passed on the merits of the
      Securities;

	 	 	 
	 	(q) 	
      no documents in connection with this Offering have been
      reviewed by the SEC or any state securities administrators;

	 	 	 
	 	(r) 	
      there is no government or other insurance covering any of
      the Securities; and

	 	 	 
	 	(s) 	
      this Subscription is not enforceable by the Subscriber
      unless it has been accepted by the Company, and the Subscriber
      acknowledges and agrees that the Company reserves the right to reject any
      Subscription for any reason.

5. Representations, Warranties and Covenants of the
Subscriber

5.1 The Subscriber hereby represents and warrants to and
covenants with the Company (which representations, warranties and covenants
shall survive the Closing Date) that:

	 	(a) 	
      the Subscriber is not a U.S. Person or a resident of
      Canada;

	 	 	 	 
	 	(b) 	
      the Subscriber is not acquiring the Securities for the
      account or benefit of, directly or indirectly, any U.S. Person or a
      resident of Canada;

	 	 	 	 
	 	(c) 	
      the Subscriber is resident in the jurisdiction set out on
      page 11 of this Subscription;

	 	 	 	 
	 	(d) 	
      the issuance of the Securities to the Subscriber as
      contemplated by the delivery of this Agreement, the acceptance of it by
      the Company and the issuance of the Securities to the Subscriber complies
      with all applicable laws of the Subscriber's jurisdiction of residence or
      domicile and will not cause the Company to become subject to or comply
      with any disclosure, prospectus or reporting requirements under any such
      applicable laws;

	 	 	 	 
	 	(e) 	
      the Subscriber:

	 	 	 	 
	 		(i) 	
      is knowledgeable of, or has been independently advised as
      to, the applicable securities laws of the securities regulators having
      application in the jurisdiction in which the Subscriber is resident (the
      “International Jurisdiction”) which would apply to the acquisition of the
      Securities,

	 	 	 	 
	 		(ii) 	
      is purchasing the Securities pursuant to exemptions from
      prospectus or equivalent requirements under applicable securities laws or,
      if such is not applicable, the Subscriber is permitted to purchase the
      Securities under the applicable securities laws of the securities
      regulators in the International Jurisdiction without the need to rely on
      any exemptions,

	 	 	 	 
	 		(iii) 	
      acknowledges that the applicable securities laws of the
      authorities in the International Jurisdiction do not require the Company
      to make any filings or seek any approvals of any kind whatsoever from any
      securities regulator of any kind whatsoever in the International
      Jurisdiction in connection with the issue and sale or resale of the
      Securities, and

- 6 -

	 		(iv) 	
      represents and warrants that the acquisition of the
      Securities by the Subscriber does not trigger:

	 	 	 	 	 
	 			A. 	
      any obligation to prepare and file a prospectus or
      similar document, or any other report with respect to such purchase in the
      International Jurisdiction, or

	 	 	 	 	 
	 			B. 	
      any continuous disclosure reporting obligation of the
      Company in the International Jurisdiction, and

	 	 	 	 	 
	 			
      the Subscriber will, if requested by the Company, deliver
        to the Company a certificate or opinion of local counsel from the
        International Jurisdiction which will confirm the matters referred to in
        subparagraphs (ii), (iii) and (iv) above to the satisfaction of the
    Company, acting reasonably;

	 	 	 	 	 
	 	(f) 	
      the Subscriber is acquiring the Securities as principal
      for investment only and not with a view to, or for, resale, distribution
      or fractionalization thereof, in whole or in part, and, in particular, it
      has no intention to distribute either directly or indirectly any of the
      Securities in the United States or to U.S. Persons;

	 	 	 	 	 
	 	(g) 	
      the Subscriber is outside the United States when
      receiving and executing this Subscription;

	 	 	 	 	 
	 	(h) 	
      the Subscriber has received and carefully read this
      Subscription;

	 	 	 	 	 
	 	(i) 	
      the Subscriber understands and agrees not to engage in
      any hedging transactions involving any of the Securities unless such
      transactions are in compliance with the provisions of the 1933 Act and in
      each case only in accordance with applicable state securities
  laws;

	 	 	 	 	 
	 	(j) 	
      the Subscriber acknowledges that it has not acquired the
      Securities as a result of, and will not itself engage in, any "directed
      selling efforts" (as defined in Regulation S under the 1933 Act) in the
      United States in respect of any of the Securities which would include any
      activities undertaken for the purpose of, or that could reasonably be
      expected to have the effect of, conditioning the market in the United
      States for the resale of any of the Securities; provided, however, that
      the Subscriber may sell or otherwise dispose of any of the Securities
      pursuant to registration of any of the Securities pursuant to the 1933 Act
      and any applicable state securities laws or under an exemption from such
      registration requirements and as otherwise provided herein;

	 	 	 	 	 
	 	(k) 	
      the Subscriber has the legal capacity and competence to
      enter into and execute this Subscription and to take all actions required
      pursuant hereto and, if the Subscriber is a corporation, it is duly
      incorporated and validly subsisting under the laws of its jurisdiction of
      incorporation and all necessary approvals by its directors, shareholders
      and others have been obtained to authorize execution and performance of
      this Subscription on behalf of the Subscriber;

	 	 	 	 	 
	 	(l) 	
      the Subscriber (i) has adequate net worth and means of
      providing for its current financial needs and possible personal
      contingencies, (ii) has no need for liquidity in this investment, and
      (iii) is able to bear the economic risks of an investment in the
      Securities for an indefinite period of time, and can afford the complete
      loss of such investment;

	 	 	 	 	 
	 	(m) 	
      the Subscriber understands and agrees that the Company
      and others will rely upon the truth and accuracy of the acknowledgements,
      representations, warranties, covenants and agreements contained in this
      Subscription and agrees that if any of such acknowledgements,
      representations and agreements are no longer accurate or have been
      breached, the Subscriber shall promptly notify the
  Company;

- 7 -

	 	(n) 	
      the Subscriber is aware that an investment in the Company
      is speculative and involves certain risks, including the possible loss of
      the investment;

	 	 	 	 
	 	(o) 	
      the entering into of this Subscription and the
      transactions contemplated hereby do not result in the violation of any of
      the terms and provisions of any law applicable to, or, if applicable, the
      constating documents of, the Subscriber, or of any agreement, written or
      oral, to which the Subscriber may be a party or by which the Subscriber is
      or may be bound;

	 	 	 	 
	 	(p) 	
      the Subscriber has duly executed and delivered this
      Subscription and it constitutes a valid and binding agreement of the
      Subscriber enforceable against the Subscriber;

	 	 	 	 
	 	(q) 	
      the Subscriber understands and agrees that the Company
      and others will rely upon the truth and accuracy of the acknowledgements,
      representations and agreements contained in this Subscription, and agrees
      that if any of such acknowledgements, representations and agreements are
      no longer accurate or have been breached, the Subscriber shall promptly
      notify the Company;

	 	 	 	 
	 	(r) 	
      all information contained in this Subscription is
      complete and accurate and may be relied upon by the Company, and the
      Subscriber will notify the Company immediately of any material change in
      any such information occurring prior to the Closing Date;

	 	 	 	 
	 	(s) 	
      the Subscriber is purchasing the Securities for its own
      account for investment purposes only and not for the account of any other
      person and not for distribution, assignment or resale to others, and no
      other person has a direct or indirect beneficial interest is such
      Securities, and the Subscriber has not subdivided his interest in the
      Securities with any other person;

	 	 	 	 
	 	(t) 	
      the Subscriber is not an underwriter of, or dealer in,
      the Securities of the Company's common stock, nor is the Subscriber
      participating, pursuant to a contractual agreement or otherwise, in the
      distribution of the Securities;

	 	 	 	 
	 	(u) 	
      the Subscriber has made an independent examination and
      investigation of an investment in the Securities and the Company and has
      depended on the advice of its legal and financial advisors and agrees that
      the Company will not be responsible in anyway whatsoever for the
      Subscriber's decision to invest in the Securities and the
  Company;

	 	 	 	 
	 	(v) 	
      if the Subscriber is acquiring the Securities as a
      fiduciary or agent for one or more investor accounts, the Subscriber has
      sole investment discretion with respect to each such account, and the
      Subscriber has full power to make the foregoing acknowledgements,
      representations and agreements on behalf of such account;

	 	 	 	 
	 	(w) 	
      the Subscriber is not aware of any advertisement of any
      of the Securities and is not acquiring the Securities as a result of any
      form of general solicitation or general advertising including
      advertisements, articles, notices or other communications published in any
      newspaper, magazine or similar media or broadcast over radio or
      television, or any seminar or meeting whose attendees have been invited by
      general solicitation or general advertising; and

	 	 	 	 
	 	(x) 	
      no person has made to the Subscriber any written or oral
      representations:

	 	 	 	 
	 		(i) 	
      that any person will resell or repurchase any of the
      Securities,

	 	 	 	 
	 		(ii) 	
      that any person will refund the purchase price of any of
      the Securities,

	 	 	 	 
	 		(iii) 	
      as to the future price or value of any of the Securities,
      or

- 8 -

	 	(iv) 	
      that any of the Securities will be listed and posted for
      trading on any stock exchange or automated dealer quotation system or that
      application has been made to list and post any of the Securities of the
      Company on any stock exchange or automated dealer quotation system, except
      that currently certain market makers make market in the Securities of the
      Company's common stock on the OTC Bulletin Board.

5.2 In this Subscription, the term "U.S. Person" shall have the
meaning ascribed thereto in Regulation S promulgated under the 1933 Act and for
the purpose of the Subscription includes any person in the United States.

6. Acknowledgement and Waiver

6.1 The Subscriber has acknowledged that the decision to
purchase the Securities was solely made on the Company Information. The
Subscriber hereby waives, to the fullest extent permitted by law, any rights of
withdrawal, rescission or compensation for damages to which the Subscriber might
be entitled in connection with the distribution of any of the Securities.

7. Representations and Warranties will be Relied
Upon by the Company

7.1 The Subscriber acknowledges that the acknowledgements,
representations and warranties contained herein are made by it with the
intention that they may be relied upon by the Company and its legal counsel in
determining the Subscriber's eligibility to purchase the Securities under
applicable securities legislation, or (if applicable) the eligibility of others
on whose behalf it is contracting hereunder to purchase the Securities under
applicable securities legislation. The Subscriber further agrees that by
accepting delivery of the certificates representing the Securities, it will be
representing and warranting that the acknowledgements representations and
warranties contained herein are true and correct as of the date hereof and will
continue in full force and effect notwithstanding any subsequent disposition by
the Subscriber of such Securities.

8. Resale Restrictions

8.1 The Subscriber acknowledges that any resale of the
Securities will be subject to resale restrictions contained in the securities
legislation applicable to the Subscriber or proposed transferee. The Subscriber
acknowledges that the Securities have not been registered under the 1933 Act or
the securities laws of any state of the United States. The Securities may not be
offered or sold in the United States unless registered in accordance with
federal securities laws and all applicable state securities laws or exemptions
from such registration requirements are available.

8.2 In addition to resale restrictions under applicable law,
the Subscriber agrees that it will not resell any of the Securities for a period
of eighteen months from the Closing date unless the Subscriber has received
written consent to the sale signed by all the directors of the Company. 

9. Legending and Registration of Subject
Securities

9.1 The Subscriber hereby acknowledges that upon the issuance
thereof, and until such time as the same is no longer required under the
applicable securities laws and regulations, the certificates representing any of
the Securities will bear a legend in substantially the following form:

  
    THE SECURITIES REPRESENTED HEREBY HAVE BEEN OFFERED IN AN
      OFFSHORE TRANSACTION TO A PERSON WHO IS NOT A U.S. PERSON (AS DEFINED HEREIN)
      PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS
      AMENDED (THE "1933 ACT").

  

- 9 -

  
    NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED
      UNDER THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO
      REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED
      STATES (AS DEFINED HEREIN) OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE
      PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE
      REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION
      FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
      1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
      LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE
      CONDUCTED UNLESS IN COMPLIANCE WITH THE 1933 ACT. "UNITED STATES" AND "U.S.
      PERSON" ARE AS DEFINED BY REGULATION S UNDER THE 1933 ACT.

    THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD
      BY THE HOLDER UNTIL (DATE WHICH IS TWO YEARS AFTER THE CLOSING DATE) WITHOUT THE
      WRITTEN CONSENT OF ALL THE DIRECTORS OF ANAVEX LIFE SCIENCES CORP. 

  

9.2 The Subscriber hereby acknowledges and agrees to the
Company making a notation on its records or giving instructions to the registrar
and transfer agent of the Company in order to implement the restrictions on
transfer set forth and described in this Subscription.

10. Costs

10.1 The Subscriber acknowledges and agrees that all costs and
expenses incurred by the Subscriber (including any fees and disbursements of any
special counsel retained by the Subscriber) relating to the purchase of the
Securities shall be borne by the Subscriber.

11. Governing Law

11.1 This Subscription is governed by the laws of the State of
Nevada and the federal laws of the United States applicable thereto. The
Subscriber, in its personal or corporate capacity and, if applicable, on behalf
of each beneficial purchaser for whom it is acting, irrevocably attorns to the
exclusive jurisdiction of the Courts of the State of Nevada.

12. Survival

12.1 This Subscription, including without limitation the
representations, warranties and covenants contained herein, shall survive and
continue in full force and effect and be binding upon the parties hereto
notwithstanding the completion of the purchase of the Securities by the
Subscriber pursuant hereto.

13. Assignment

13.1 This Subscription is not transferable or assignable.

14. Severability

14.1 The invalidity or unenforceability of any particular
provision of this Subscription shall not affect or limit the validity or
enforceability of the remaining provisions of this Subscription.

- 10 -

15. Entire Agreement

15.1 Except as expressly provided in this Subscription and in
the agreements, instruments and other documents contemplated or provided for
herein, this Subscription contains the entire agreement between the parties with
respect to the sale of the Securities and there are no other terms, conditions,
representations or warranties, whether expressed, implied, oral or written, by
statute or common law, by the Company or by anyone else.

16. Notices

16.1 All notices and other communications hereunder shall be in
writing and shall be deemed to have been duly given if mailed or transmitted by
any standard form of telecommunication. Notices to the Subscriber shall be
directed to the address on page 11 and notices to the Company shall be directed
to it at the first page of this Subscription.

17. Counterparts and Electronic Means

1.1 This Subscription may be executed in any number of
counterparts, each of which, when so executed and delivered, shall constitute an
original and all of which together shall constitute one instrument. Delivery of
an executed copy of this Subscription by electronic facsimile transmission or
other means of electronic communication capable of producing a printed copy will
be deemed to be execution and delivery of this Subscription as of the date
hereinafter set forth.

- 11 -

IN WITNESS WHEREOF the Subscriber has duly executed this
Subscription as of the date hereinafter set forth.

DELIVERY AND REGISTRATION INSTRUCTIONS

	1. 	
      Delivery - please deliver the Share certificates
    to:

	 	 
	 	 
	 	 
	 	 
	 	 
	2. 	
      Registration - registration of the certificates which are
      to be delivered at closing should be made as follows (if different from
      above):

	 	 
	 	 
		
      (name)

	 	 
	 	 
		
      (address)

	 	 
	3. 	
      The undersigned hereby acknowledges that he or she will
      deliver to the Company all such additional completed forms in respect of
      the Subscriber's purchase of the Securities as may be required for filing
      with the appropriate securities commissions and regulatory
    authorities.

	 	 
	 	(Name of Subscriber – Please type or print)
  
	 	 
	 	 
	 	(Signature and, if applicable, Officer title)
    
	 	 
	 	 
	 	(Address of Subscriber) 
	 	 
	 	 
	 	(City, State, and Zip Code of Subscriber)

	 	 
	 	 
	 	(Country of Subscriber) 
	 	 
	 	 
	 	(Fax Number and email address) 
	 	  
	 	 
	 	(Number of Units to be Purchased) 
	 	 
	 	 
	 	(Total Subscription Price)

- 12 -

A C C E P T A N C E

The above-mentioned Subscription in respect of the Units is
hereby accepted by ANAVEX LIFE SCIENCES CORP.

DATED at ____________________________, the _____day of
______________, 200_.

ANAVEX LIFE SCIENCES CORP.

	Per:	 
	 	Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]